Nektar Therapeutics buy Oppenheimer Holdings Inc.
Start price
13.03.26
/
50%
€0.58
Target price
13.03.27
-
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 13.03.27. The prediction end date can be changed by Oppenheimer_Holdings at any time.Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Nektar Therapeutics | - | - |
| iShares Core DAX® | 3,59 % | 6,43 % |
| iShares Nasdaq 100 | 5,81 % | 6,38 % |
| iShares Nikkei 225® | 4,08 % | 9,31 % |
| iShares S&P 500 | 4,14 % | 4,94 % |
Comments by Oppenheimer_Holdings for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NKTR) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
Ratings data for NKTR provided by MarketBeat
Stopped prediction by Oppenheimer_Holdings for Nektar Therapeutics
Nektar Therapeutics
Start price
Target price
Perf. (%)
€0.82
14.03.25
14.03.25
€5.53
14.03.26
14.03.26
-29.01%
15.03.26
15.03.26
